0W4N Stock Chart & Stats
€18.96
-€0.06(-0.32%)
At close: 4:00 PM EDT
€18.96
-€0.06(-0.32%)
Day’s Range― - ―
52-Week Range€15.90 - €26.85
Previous CloseN/A
Volume15.00
Average Volume (3M)298.00
Market Cap
€340.03M
Enterprise Value€304.89
Total Cash (Recent Filing)€51.78M
Total Debt (Recent Filing)€8.52M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 12, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding17,672,928
10 Day Avg. Volume403
30 Day Avg. Volume298
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.13
Price to Sales (P/S)10.17
P/FCF Ratio-10.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€33.00Price Target Upside74.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.32
Revenue Forecast (FY)€79.02M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetLow leverage and substantial equity provide financial flexibility to fund biosimilar development and absorb volatility. This reduces near-term balance-sheet risk, although continued losses could gradually weaken that support.
Improved Operating Cash FlowThe shift to positive operating cash flow indicates that core activities generated more internal funding in 2025. If sustained, this could reduce reliance on external financing as development programs mature.
Asset-Light Partner CommercializationPartner-led commercialization can limit selling infrastructure requirements while preserving participation in product economics. This model may support scalable expansion across markets as additional biosimilars reach approval and launch.
Bears Say
Recent Revenue ContractionTwo consecutive years of revenue contraction weaken visibility into commercial momentum and may reflect volatility in milestones, launches, or product-related income. Sustained declines could constrain investment capacity and partner negotiating leverage.
Unstable ProfitabilityThe sharp move from profits to substantial losses shows that earnings are highly dependent on program timing and commercialization events. This limits predictability and makes durable self-funded growth more difficult.
Persistent Free Cash Flow BurnHeavy investment and spending needs are not currently covered by operating inflows, creating a structural funding risk. If negative free cash flow persists, the company may need financing that could reduce flexibility or dilute shareholders.
Formycon AG News
0W4N FAQ
What was Formycon AG’s price range in the past 12 months?
Formycon AG lowest share price was €15.90 and its highest was €26.85 in the past 12 months.
What is Formycon AG’s market cap?
Formycon AG’s market cap is €340.03M.
When is Formycon AG’s upcoming earnings report date?
Formycon AG’s upcoming earnings report date is Nov 12, 2026 which is in 70 days.
How were Formycon AG’s earnings last quarter?
Formycon AG released its earnings results on Aug 12, 2026. The company reported -€0.83 earnings per share for the quarter, missing the consensus estimate of -€0.14 by -€0.69.
Is Formycon AG overvalued?
According to Wall Street analysts Formycon AG’s price is currently Undervalued.
Does Formycon AG pay dividends?
Formycon AG pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Formycon AG dividends here
What is Formycon AG’s EPS estimate?
Formycon AG’s EPS estimate is -0.04.
How many shares outstanding does Formycon AG have?
Formycon AG has 17,672,928 shares outstanding.
What happened to Formycon AG’s price movement after its last earnings report?
Formycon AG reported an EPS of -€0.83 in its last earnings report, missing expectations of -€0.14. Following the earnings report the stock price went down -0.211%.
Which hedge fund is a major shareholder of Formycon AG?
Currently, no hedge funds are holding shares in GB:0W4N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Formycon AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Formycon AG
Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar equivalent to Lucentis, which is intended for the treatment of neovascular age-related macular degeneration and other severe eye conditions. The company is also progressing with FYB202, a biosimilar of Stelara, currently undergoing Phase III clinical trials for various inflammatory diseases, including moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Additionally, FYB203, a biosimilar candidate for Eylea, is in Phase III clinical trials, aiming to address similar ocular diseases like neovascular age-related macular degeneration. Further endeavors include the development of FYB206 and FYB207, with the latter being an antiviral treatment for COVID-19. To ensure the stability of its numerous drug candidates, Formycon AG maintains a collaborative agreement with Leukocare AG.
0W4N Stock 12 Month Forecast
Average Price Target
€33.00
▲(74.05% Upside)
Technical Analysis
B.R.A.I.N. Biotechnology Research and Information Network
―
co.don AG
―
Medigene
―
Heidelberg Pharma AG
―
MagForce AG
―